Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.

In the 2-year final analysis of the phase 3 PROTECT trial, sparsentan produced a sustained 40% greater reduction in proteinuria and slowed eGFR decline versus maximally titrated irbesartan in adults with IgA nephropathy, with a comparable safety profile.